PET-imaging in drug development
Positron emission tomography (PET) is the most selective and sensitive (picomolar level) method for measuring molecular pathways and interactions in vivo. [18F]FDG PET is now accepted as a surrogate endpoint in the evaluation of novel anti-cancer therapies. Apart from this well-known application, PET has more to offer to drug development and treatment evaluation. It provides an in vivo means for determining both optimal dose and optimal dosing regimen for drugs that target receptors and/or enzymes. In addition, by labelling a drug with a positron emitter, it is possible to follow the fate of that drug in the human body and to establish whether local tissue concentrations are high enough for expecting a pharmacological effect.